ABSTRACT Introduction: Butyrylcholinesterase (BuChE) has obtained a renewed interest as
therapeutic target in Alzheimer's disease (AD), when changes in BuChE activity and …

Introduction Alzheimer's disease (AD) constitutes one of the most devastating diseases, with
an extraordinarily high increase expected for the next few years. Despite the numerous …

Alzheimer's disease (AD) is one of the most prevalent neurodegenerative disorders with
notable factor of dysfunction in cholinergic system. Low ACh level can be observed in the …

Alzheimer's disease (AD) is a progressive neurodegenerative disorder of the elderly,
characterised by widespread loss central cholinergic function. The only symptomatic …

Acetylcholinesterase (AChE) predominates in the healthy brain, with butyrylcholinesterase
(BuChE) considered to play a minor role in regulating brain acetylcholine (ACh) levels …

Objective: To examine the role of butyrylcholinesterase (BuChE) in cholinergic signaling and
neurologic conditions, such as Alzheimer's disease (AD). The rationale for inhibiting …

Acetylcholinesterase (AChE) inhibitor is the first choice for the treatment of Alzheimer's
disease (AD), but it has some defects, such as dose limitation and unsatisfactory long-term …

Highlights•BChE is considered a promising drug target for the treatment of moderate to
severe Alzheimer's disease.•The development of selective BChE inhibitors will move on …

The serine hydrolase butyrylcholinesterase (BChE), like the related enzyme
acetylcholinesterase (AChE), co-regulates metabolism of the neurotransmitter acetylcholine …

Cholinesterase inhibitors are the standard of care for Alzheimer's disease (AD).
Acetylcholinesterase (AChE) catalyzes the hydrolysis of the cholinergic neurotransmitter …